mRNA and lncRNA Expression Profiling of Radiation-Induced Gastric Injury Reveals Potential Radiation-Responsive Transcription Factors

Chen, Guangxia; Feng, Yali; Sun, Zhiqiang; Gao, Yiying; Wu, Chuannan; Zhang, Haihan; Cao, Jinming; Chen, Zhuo; Cao, Jianping; Zhu, Yaqun; Zhang, Shuyu

doi:10.1177/1559325819886766

Cited by 14 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As most of these lncRNAs have very low expression in the brain and it increased after brain injury, it indicates that these lncRNAs might be involved in pathological mechanisms in TBI. Some lncRNAs are thought to become transcriptional regulators 25 that regulate coding gene expression by cis or trans mechanisms. Unfortunately, there are very few studies that have investigated the association of these differentially expressed lncRNAs with TBI especially on cis or trans mechanisms.…”

Section: Discussionmentioning

confidence: 99%

Expression Profiles of Long Non-coding RNA and Messenger RNA in Human Traumatic Brain Injury

Ren

Chen

Cao

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) play an important role in central nervous diseases; however, the exact expression and co-expressed profiles in human traumatic brain injury (TBI) are still unknown. Therefore, we investigated whole blood in 12 patients with TBI and 4 healthy controls to observe expression characteristics with different severity. We identified 3,035 lncRNAs and 1,204 mRNAs differentially expressed in the severe TBI group, 2,362 lncRNAs and 656 mRNAs in the moderate group, and 433 lncRNAs and 100 mRNAs in the mild group. Enrichment analyses showed 30 signaling pathways such as inflammatory and immune response pathways. Subsequently, a lncRNA-gene co-expression network was generated for 717 lncRNA-mRNA pairs and most of them with a positive correlation. Based on GSEA analysis, we found that TBI caused severe immune abnormality reflected on Th1, Th2, and Th17 cell differentiation deficiency. Finally, the expression of one upregulated and one downregulated lncRNA was validated in all three TBI groups, which was consistent with the microarray results. In summary, our results show that expression profiles of lncRNAs and mRNAs are significantly different in bloods from different severity TBI especially in immune response, providing novel insight for lncRNAs in human TBI.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression Profiles of Long Non-coding RNA and Messenger RNA in Human Traumatic Brain Injury

Ren

Chen

Cao

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…A recent study on FGL1-mediated targeted therapy resistance have also been reported in HCC [116]. In addition, although FGL1 is a mediator of radiation injury [71][72][73], the correlation between FGL1 and radiation sensitivity needs to be confirmed by additional studies.…”

Section: Fgl1 Regulates Other Tumor Characteristicsmentioning

confidence: 99%

“…Given that FGL1 is a physiological secretory factor of the liver, its expression can be regarded as a self-protective mechanism acting against exogenous injury or stimulation. FGL1 expression is regulated by radiation-induced lung, liver and stomach injury [71][72][73]. In addition, factors released by hepatectomy and postoperative inflammation (interleukin (IL)-6 and transforming growth factor (TGF)-β) can also affect the expression of FGL1 [70,[73][74][75][76][77].…”

Section: Expression Regulation and Function Of Fgl1 In Benign Diseasementioning

confidence: 99%

See 1 more Smart Citation

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Zhao

Wang

et al. 2021

J Hematol Oncol

View full text Add to dashboard Cite

Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) have progressed to first-line monotherapies in certain tumor types. However, the efficacy of anti-PD-1/PD-L1 mAbs is still limited due to toxic side effects and de novo or adaptive resistance. Moreover, other immune checkpoint target and biomarkers for therapeutic response prediction are still lacking; as a biomarker, the PD-L1 (CD274, B7-H1) expression level is not as accurate as required. Hence, it is necessary to seek more representative predictive molecules and potential target molecules for immune checkpoint therapy. Fibrinogen-like protein 1 (FGL1) is a proliferation- and metabolism-related protein secreted by the liver. Multiple studies have confirmed that FGL1 is a newly emerging checkpoint ligand of lymphocyte activation gene 3 (LAG3), emphasizing the potential of targeting FGL1/LAG3 as the next generation of immune checkpoint therapy. In this review, we summarize the substantial regulation mechanisms of FGL1 in physiological and pathological conditions, especially tumor epithelial to mesenchymal transition, immune escape and immune checkpoint blockade resistance, to provide insights for targeting FGL1 in cancer treatment.

show abstract

“…Chen and colleagues [ 109 ] observed that the expression of IRX4 was modulated in gastric tissues in response to ionizing radiation. They found that IRX4 was downregulated in the mouse stomach after irradiation with 6 or 12 Gy X-rays, and they also observed that radiation resulted in atrophy of the gastric mucosa and abnormal morphology of chief and parietal cells.…”

Section: Iroquois Family Genes In Gastric Cancermentioning

confidence: 99%

Iroquois Family Genes in Gastric Carcinogenesis: A Comprehensive Review

Santos

Petrone

Binato

et al. 2023

Genes

View full text Add to dashboard Cite

Gastric cancer (GC) is the fifth leading cause of cancer-associated death worldwide, accounting for 768,793 related deaths and 1,089,103 new cases in 2020. Despite diagnostic advances, GC is often detected in late stages. Through a systematic literature search, this study focuses on the associations between the Iroquois gene family and GC. Accumulating evidence indicates that Iroquois genes are involved in the regulation of various physiological and pathological processes, including cancer. To date, information about Iroquois genes in GC is very limited. In recent years, the expression and function of Iroquois genes examined in different models have suggested that they play important roles in cell and cancer biology, since they were identified to be related to important signaling pathways, such as wingless, hedgehog, mitogen-activated proteins, fibroblast growth factor, TGFβ, and the PI3K/Akt and NF-kB pathways. In cancer, depending on the tumor, Iroquois genes can act as oncogenes or tumor suppressor genes. However, in GC, they seem to mostly act as tumor suppressor genes and can be regulated by several mechanisms, including methylation, microRNAs and important GC-related pathogens. In this review, we provide an up-to-date review of the current knowledge regarding Iroquois family genes in GC.

show abstract

mRNA and lncRNA Expression Profiling of Radiation-Induced Gastric Injury Reveals Potential Radiation-Responsive Transcription Factors

Cited by 14 publications

References 35 publications

Expression Profiles of Long Non-coding RNA and Messenger RNA in Human Traumatic Brain Injury

Expression Profiles of Long Non-coding RNA and Messenger RNA in Human Traumatic Brain Injury

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Iroquois Family Genes in Gastric Carcinogenesis: A Comprehensive Review

Contact Info

Product

Resources

About